Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · IEX Real-Time Price · USD
2.390
-0.060 (-2.45%)
At close: Jul 19, 2024, 4:00 PM
2.420
+0.030 (1.26%)
Pre-market: Jul 22, 2024, 9:03 AM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 240 employees as of December 31, 2023. The number of employees increased by 41 or 20.60% compared to the previous year.
Employees
240
Change (1Y)
41
Growth (1Y)
20.60%
Revenue / Employee
$957,250
Profits / Employee
-$360,446
Market Cap
407.30M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Sonida Senior Living | 3,955 |
Cerus | 637 |
AxoGen | 428 |
Anika Therapeutics | 357 |
Editas Medicine | 265 |
Lyell Immunopharma | 224 |
Precigen | 202 |
C4 Therapeutics | 145 |
ESPR News
- 6 days ago - New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries - GlobeNewsWire
- 24 days ago - Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility - GlobeNewsWire
- 2 months ago - Esperion to Participate in Upcoming June Investor Conferences - GlobeNewsWire
- 2 months ago - Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia - GlobeNewsWire
- 2 months ago - Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® - GlobeNewsWire
- 2 months ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Esperion Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Esperion to Participate in Upcoming May Investor Conferences - GlobeNewsWire